- Home
- NXN vs ELEV Comparison
NXN vs ELEV Comparison
Compare NXN & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- ELEV
- Stock Information
- Founded
- NXN 1992
- ELEV 2019
- Country
- NXN United States
- ELEV United States
- Employees
- NXN N/A
- ELEV N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- ELEV Health Care
- Exchange
- NXN Nasdaq
- ELEV Nasdaq
- Market Cap
- NXN 44.9M
- ELEV 37.6M
- IPO Year
- NXN N/A
- ELEV 2021
- Fundamental
- Price
- NXN $11.66
- ELEV $0.71
- Analyst Decision
- NXN
- ELEV Buy
- Analyst Count
- NXN 0
- ELEV 6
- Target Price
- NXN N/A
- ELEV $7.20
- AVG Volume (30 Days)
- NXN 9.7K
- ELEV 4.2M
- Earning Date
- NXN 01-01-0001
- ELEV 03-05-2025
- Dividend Yield
- NXN 4.23%
- ELEV N/A
- EPS Growth
- NXN N/A
- ELEV N/A
- EPS
- NXN 0.24
- ELEV N/A
- Revenue
- NXN N/A
- ELEV N/A
- Revenue This Year
- NXN N/A
- ELEV N/A
- Revenue Next Year
- NXN N/A
- ELEV N/A
- P/E Ratio
- NXN $48.42
- ELEV N/A
- Revenue Growth
- NXN N/A
- ELEV N/A
- 52 Week Low
- NXN $10.64
- ELEV $0.50
- 52 Week High
- NXN $12.45
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- NXN 58.29
- ELEV 53.28
- Support Level
- NXN $11.26
- ELEV $0.65
- Resistance Level
- NXN $11.89
- ELEV $0.98
- Average True Range (ATR)
- NXN 0.09
- ELEV 0.11
- MACD
- NXN 0.04
- ELEV 0.00
- Stochastic Oscillator
- NXN 63.92
- ELEV 36.63
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.